{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:50Z","timestamp":1772119250776,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Introduction: We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA\u2009+\u2009Ven) who achieved complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (CRi), or morphologic leukemia-free state (MLFS) as defined by ELN 2022. Methods: Patients with AML seen at Moffitt Cancer Center between 2018 and 2022 and treated with HMA\u2009+\u2009Ven were retrospectively evaluated. Results: About 120 patients achieved blast clearance with best response of CR in 52 (43.3%), CRh in 22 (18.3%), CRi in 31 (25.8%) and MLFS in 15 (12.5%) patients. Greater proportion of patients with MLFS had a prior myeloid malignancy (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) and were treated with prior HMA (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Patients that achieved MLFS as their best response had inferior OS compared to the CR\/CRh\/CRi cohort (8 months vs. 27 months;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). RFS was also worse for the MLFS cohort. Conclusion: To the best of our knowledge, this is the largest study analyzing differences in outcomes of AML patients treated with HMA\u2009+\u2009Ven based on best response. We noted that prior myeloid malignancy and use of HMA led to more MLFS as best response compared to CR\/CRi. The OS and RFS were inferior for MLFS cohort.\n                  <\/jats:p>","DOI":"10.1007\/s00277-024-05976-6","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T02:02:12Z","timestamp":1725674532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia"],"prefix":"10.1007","author":[{"given":"Akriti G.","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia O.","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tobon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra L.","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"1","key":"5976_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3324\/haematol.2021.280161","volume":"107","author":"JM Rowe","year":"2022","unstructured":"Rowe JM (2022) The 7\u2009+\u20093 regimen in acute myeloid leukemia. Haematologica 107(1):3","journal-title":"Haematologica"},{"issue":"3","key":"5976_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401\u2013407","journal-title":"Am J Hematol"},{"issue":"7","key":"5976_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"3","key":"5976_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood 126(3):291\u2013299","journal-title":"Blood"},{"issue":"Supplement 1","key":"5976_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2022-158518","volume":"140","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat VA, Thirman MJ, Garcia JS, Fiedler W et al (2022) Long-term follow-up of the phase 3 Viale-a clinical trial of Venetoclax Plus Azacitidine for patients with untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy. Blood 140(Supplement 1):529\u2013531","journal-title":"Blood"},{"issue":"20","key":"5976_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"12","key":"5976_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"key":"5976_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0021-9681(61)90118-7","volume":"14","author":"EJ FREIREICH","year":"1961","unstructured":"FREIREICH EJ, GEHAN EA, SULMAN D, BOGGS DR, FREI E (1961) The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14:593\u2013608","journal-title":"J Chronic Dis"},{"key":"5976_CR9","doi-asserted-by":"publisher","first-page":"100806","DOI":"10.1016\/j.blre.2021.100806","volume":"48","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Pollyea DA, Zeidan AM (2021) The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses. Blood Rev 48:100806","journal-title":"Blood Rev"},{"issue":"24","key":"5976_CR10","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"C BD","year":"2003","unstructured":"BD C, JM B, KJ K, CL TB (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649","journal-title":"J Clin Oncol"},{"issue":"5","key":"5976_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/14712598.1.5.893","volume":"1","author":"EL Sievers","year":"2001","unstructured":"Sievers EL (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 1(5):893\u2013901","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"5976_CR12","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","volume":"28","author":"RB Walter","year":"2010","unstructured":"Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM et al (2010) Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 28(10):1766\u20131771","journal-title":"J Clin Oncol"},{"key":"5976_CR13","doi-asserted-by":"crossref","unstructured":"Siddiqui M, Maiti A, Daver N, Kadia T, Rausch C, Alvarado Y et al (2021) AML-310: Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine. Clinical Lymphoma, Myeloma and Leukemia. ;21:S303-S4","DOI":"10.1016\/S2152-2650(21)01721-3"},{"issue":"9","key":"5976_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125(9):1367\u20131376","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05976-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05976-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05976-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T02:03:19Z","timestamp":1725674599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05976-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":14,"alternative-id":["5976"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05976-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3977225\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study. IRB approval for this study was obtained and consent from each participant is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"VOV, CW, SB, KT: No conflicts of interest to declare. AGJ: Speakers Bureau: Rigel. OC: Research Funding: Syntrix Pharmaceuticals. EP: Research Funding: Bristol Myers Squibb, Syntrix Pharmaceuticals, Kura, Incyte; Honoraria: Taiho, Stemline, Blueprint. AK: Research Support: Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, Morphosys; Consultancy: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Honoraria: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Speakers Bureau: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma. RK: Consultancy: Servier, AbbVie, Geron, Acceleron Pharma, Taiho Oncology, Novartis, Jazz Pharmaceuticals, Bristol Myers Squibb; Honoraria: Servier, AbbVie, CTI BioPharma, Innovent, PharmaEssentia, Takeda, Jazz Pharmaceuticals, Bristol Myers Squibb; Speakers Bureau: Servier, AbbVie, Jazz Pharmaceuticals; Advisory board: CTI BioPharma, Taiho Oncology, PharmaEssentia, Takeda, Novartis, Bristol Myers Squibb; Speakers Bureau: Bristol Myers Squibb; Research Funding: Bristol Myers Squibb. JEL: Consultancy: Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novartis, Agios\/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma\/Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, Servier; Research Funding: Syntrix Pharmaceuticals, Celgene\/ Bristol Myers Squibb. DAS: Advisory Board: Intellia, Aprea, Syndax, Bristol Myers Squibb, Nemucore, Agios, AbbVie, Kite, Shattuck Labs, Novartis; Consultancy: Takeda, Novartis, Magenta; Speakers Bureau: Bristol Myers Squibb, Incyte; Research funding: Aprea, Syntrix Pharmaceuticals; Patents & Royalties: Lixte. KS: Consultancy: Pfizer, Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Advisory board: Pfizer, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Research funding: Pfizer, Syntrix Pharmaceuticals, Incyte; Honoraria: Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"AGJ: Speakers Bureau: RigelVOV, CW, SB, KT: No conflicts of interest to declare.OC: Research Funding: Syntrix PharmaceuticalsEP: Research Funding: Bristol Myers Squibb, Syntrix Pharmaceuticals, Kura, Incyte; Honoraria: Taiho, Stemline, BlueprintAK: Research Support: Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, Morphosys; Consultancy: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Honoraria: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Speakers Bureau: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI BiopharmaRK: Consultancy: Servier, AbbVie, Geron, Acceleron Pharma, Taiho Oncology, Novartis, Jazz Pharmaceuticals, Bristol Myers Squibb; Honoraria: Servier, AbbVie, CTI BioPharma, Innovent, PharmaEssentia, Takeda, Jazz Pharmaceuticals, Bristol Myers Squibb; Speakers Bureau: Servier, AbbVie, Jazz Pharmaceuticals; Advisory board: CTI BioPharma, Taiho Oncology, PharmaEssentia, Takeda, Novartis, Bristol Myers Squibb; Speakers Bureau: Bristol Myers Squibb; Research Funding: Bristol Myers Squibb.JEL: Consultancy: Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novartis, Agios\/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma\/Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, Servier; Research Funding: Syntrix Pharmaceuticals, Celgene\/ Bristol Myers SquibbDAS: Advisory Board: Intellia, Aprea, Syndax, Bristol Myers Squibb, Nemucore, Agios, AbbVie, Kite, Shattuck Labs, Novartis; Consultancy: Takeda, Novartis, Magenta; Speakers Bureau: Bristol Myers Squibb, Incyte; Research funding: Aprea, Syntrix Pharmaceuticals; Patents & Royalties: LixteKS: Consultancy: Pfizer, Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Advisory board: Pfizer, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Research funding: Pfizer, Syntrix Pharmaceuticals, Incyte; Honoraria: Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}